Boundless Bio, Inc. (BOLD)
Nasdaq: BOLD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 9, 2026 | Mar 27, 2025 | · |
| Research and development | 44,845 | 55,267 | 42,637 |
| General and administrative | 18,707 | 18,000 | 12,159 |
| Total operating expenses | 63,552 | 73,267 | 54,796 |
| Operating income | -63,552 | -73,267 | -54,796 |
| Interest and investment income | 5,357 | 7,892 | 5,282 |
| Other income (expense), net | -2 | 12 | 80 |
| Total non-operating income (expense) | 5,355 | 7,904 | 5,362 |
| Income tax expense | 0 | 0 | · |
| Net income including non-controlling interests | -58,197 | -65,363 | -49,434 |
| Net income | -58,197 | -65,363 | -49,434 |
| Earnings per share, basic | -2.60 | -3.85 | -40.65 |
| Earnings per share, diluted | -2.60 | -3.85 | -40.65 |
| Weighted average shares, basic | 22,360 | 16,984 | 1,216 |
| Weighted average shares, diluted | 22,360 | 16,984 | 1,216 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding